NCT00039715

Brief Summary

The purpose of this study is to determine whether people who develop Post-Traumatic Stress Disorder (PTSD) after a trauma have increased sensitivity to the effects of a stress hormone. Patients with PTSD have small hippocampal volume and deficits in hippocampal-mediated memory as compared to healthy people. However, it is unclear whether the smaller hippocampi are a consequence of PTSD or a risk factor for the development of PTSD. Some researchers believe that people who develop PTSD have an increase in cortisol levels during traumatic experiences and that this could be neurotoxic to the hippocampus. Others hypothesize that increased sensitivity of glucocorticoid receptors to cortisol, regardless of the cortisol levels, could lead to neurotoxic damage to the hippocampus. This study will compare responses to a stress hormone in patients with PTSD, participants who have experienced trauma but do not have PTSD, and healthy volunteers. Participants will be screened with a medical and psychiatric interview, physical examination, blood tests, electrocardiogram, and an emotional intelligence evaluation. Those eligible for the study will be asked to collect urine and saliva samples for 3 days. Participation will also include blood draws, a PET scan (brain imaging), an eye-blink test, neuropsychological testing, and other procedures. At another study visit, participants will undergo a magnetic resonance imaging (MRI) scan (brain imaging), questionnaires, and other procedures.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
93

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2002

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2002

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

June 6, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 7, 2002

Completed
2.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2004

Completed
Last Updated

March 4, 2008

Status Verified

September 1, 2004

First QC Date

June 6, 2002

Last Update Submit

March 3, 2008

Conditions

Keywords

Glucocorticoid ReceptorTraumatic RemindersStressHippocampusFlashbacksPTSDType II GR ReceptorHydrocortisoneMemoryMajor DepressionPost-Traumatic Stress DisorderHealthy VolunteerHVNormal Control

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • The study sample will consist of:
  • Patients with a primary diagnosis of PTSD due to non-combat or combat related trauma according to DSM-IV.
  • Subjects with non-combat related traumatic experiences without current PTSD and
  • Healthy subjects without current or past history of psychiatric or major medical illness.
  • All subjects will be between 18 and 60 years old.
  • Male and female subjects will be included.
  • All subjects must be able to give written informed consent prior to participation in this study.
  • Patients with PTSD must score greater than or equal to 50 on Clinician-Administered PTSD Scale as a measure of PTSD symptom severity to be included in the study.
  • Patients who are not currently on medications for PTSD. (Patients will not be discontinued from effective medication for purposes of the study).
  • Patients who are nonresponders to other psychotropic drugs must have discontinued them for at least 2 weeks prior to the first PET scan. Medications will be discontinued under the supervision of the treating physician or a research psychiatrist listed in the protocol. (Nonresponders will be defined as subjects who continue to meet criteria for PTSD despite treatment with 30 mg equivalent of paroxetine for a minimum duration of six weeks).

You may not qualify if:

  • Subjects with a clinically significant cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder.
  • Patients who would be unable to comply with study procedures or assessments.
  • Subjects with primary trauma related to motor vehicle accidents.
  • Patients who meet DSM-IV criteria for alcohol and/or substance abuse or substance dependence within 6 months prior to screening.
  • Patients who are currently on fluoxetine (Justification: Washout from fluoxetine could take up to six weeks).
  • Patients who are currently at high risk for homicide or suicide.
  • Subjects with a current or past history of other axis I disorders like schizophrenia, schizoaffective disorder, bipolar disorder or dementia will be excluded from the study. However, those with a comorbid history of other Axis 1 disorder like major depression, dysthymia or panic disorder will be included in the study. Justification: Approximately 70% of subjects with PTSD have comorbid depression and or alcohol abuse; reviewed in 134. Restricting the sample to PTSD patients without depression will not accurately reflect the biology of this disorder\].
  • Subjects with a history of peptic ulcer disease will be excluded. (Justification: Those with a history of acid peptic disease requiring antacids in the past will be excluded, although it is unlikely that a single dose of intravenous hydrocortisone could precipitate bleeding due to gastritis or peptic ulcer disease).
  • Women of childbearing potential who are not practicing a clinically accepted method of contraception or who have a positive pregnancy test or who are lactating.
  • Subjects who donated a Red Cross unit of blood within 60 days prior to participation in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institute of Mental Health (NIMH)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Bremner JD, Randall P, Scott TM, Capelli S, Delaney R, McCarthy G, Charney DS. Deficits in short-term memory in adult survivors of childhood abuse. Psychiatry Res. 1995 Nov 29;59(1-2):97-107. doi: 10.1016/0165-1781(95)02800-5.

    PMID: 8771224BACKGROUND
  • Bremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM, Delaney RC, McCarthy G, Charney DS, Innis RB. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry. 1995 Jul;152(7):973-81. doi: 10.1176/ajp.152.7.973.

    PMID: 7793467BACKGROUND
  • Bremner JD, Randall P, Vermetten E, Staib L, Bronen RA, Mazure C, Capelli S, McCarthy G, Innis RB, Charney DS. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse--a preliminary report. Biol Psychiatry. 1997 Jan 1;41(1):23-32. doi: 10.1016/s0006-3223(96)00162-x.

    PMID: 8988792BACKGROUND

MeSH Terms

Conditions

Stress Disorders, Post-TraumaticDepressive Disorder, Major

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental DisordersDepressive DisorderMood Disorders

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

June 6, 2002

First Posted

June 7, 2002

Study Start

June 1, 2002

Study Completion

September 1, 2004

Last Updated

March 4, 2008

Record last verified: 2004-09

Locations